Neuro, You're the expert, so I'll defer to your knowledge of the sector. But without that type info, it's almost impossible to gauge CX-717's chances. One could also argue that the info I mentioned is clearly material to the future of the company. In that case, not revealing it would theoretically run afoul of the SEC disclosure rules and open up the company to lawsuits later on.
Another more practical aspect is that if a little more info was known, perhaps the stock price might not be as far down into the toilet as it is. Of course the opposite could also be true, IF the added info was negative - like an upper longer term dosing limit of 100-200 mg, for example. That's my fear, and suspicion, fwiw.
Market Data 
Markets 
AI
